Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp

Equities researchers at Citizens Jmp began coverage on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage set a “market outperform” rating and a $34.00 price target on the stock. Citizens Jmp’s price objective indicates a potential upside of 51.38% from the company’s previous close.

Several other research firms have also commented on LYEL. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price objective for the company from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $39.50.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock opened at $22.46 on Monday. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $45.00. The company has a market cap of $477.05 million, a price-to-earnings ratio of -0.98 and a beta of -0.14. The firm has a 50 day moving average price of $24.85 and a 200 day moving average price of $21.14.

Insider Activity at Lyell Immunopharma

In related news, CEO Lynn Seely sold 7,455 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $174,372.45. Following the completion of the transaction, the chief executive officer owned 74,266 shares of the company’s stock, valued at approximately $1,737,081.74. This represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Gary K. Lee sold 1,671 shares of Lyell Immunopharma stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $39,084.69. Following the sale, the insider owned 16,938 shares in the company, valued at $396,179.82. This represents a 8.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 11,310 shares of company stock valued at $264,285. Insiders own 22.30% of the company’s stock.

Hedge Funds Weigh In On Lyell Immunopharma

A number of hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. acquired a new position in Lyell Immunopharma in the fourth quarter valued at approximately $3,036,000. MWG Caph Ltd acquired a new position in Lyell Immunopharma during the 4th quarter valued at about $31,030,000. ExodusPoint Capital Management LP bought a new position in Lyell Immunopharma during the 4th quarter valued at $262,000. Barclays PLC grew its stake in shares of Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after purchasing an additional 14,775 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Lyell Immunopharma in the 4th quarter worth approximately $2,257,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.